Brief: Verastem Oncology and Yakult Honsha sign agreement for development, commercialization of Duvelisib in Japan
05/06/2018 09:36
June 5 (Reuters) - Verastem Inc:
* VERASTEM ONCOLOGY AND YAKULT HONSHA CO., LTD. SIGN
EXCLUSIVE
LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF
DUVELISIB IN JAPAN
* VERASTEM - CO TO RECEIVE UPFRONT PAYMENT OF $10 MILLION
USD,THEN
ELIGIBLE TO RECEIVE UP TO $90 MILLION USD IN FUTURE MILESTONES,
PLUS ROYALTIES
Source text for Eikon: ID:nBw4GK49Ka
Further company coverage: 2267.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Yakult Honsha
See all newsBrief: Dalton Investments Sends Letter To Yakult Honsha
Table: Yakult -Q1 group results
To Cancel 5.53 Million Shares, 1.79% Of Outstanding Shares, On June 30
Japanese firms field record proposals from activists at this year's shareholder meetings
Brief: Murakami-Linked City Index Eleventh Takes 1.6% Stake In Yakult Honsha Co, AGM Notice Shows